New Product Development in Pharma: The Go-To-Market Gap Nobody Talks About

New product development in the pharmaceutical industry is one of the most expensive, regulated, and commercially complex processes in any sector. The science gets enormous attention. The marketing rarely does, and that gap costs companies more than they admit.

Getting a drug or medical device from pipeline to commercial success is not just a clinical challenge. It is a go-to-market challenge, and treating it as anything less is where many pharma launches quietly fail.

I have spent more than two decades running agencies and building marketing strategies across 30 industries, including healthcare and life sciences. The pattern I see in pharma go-to-market is consistent: the science team is meticulous and the marketing team is scrambling. Clinical timelines are mapped to the week. Launch marketing plans are often assembled in the final six months before approval. That asymmetry is not a culture problem. It is a structural one, and it is fixable.

Why Pharma Product Launches Fail Commercially

The pharmaceutical industry has a specific version of a problem that exists across every sector I have worked in. Companies spend years perfecting the product and weeks perfecting the market entry. When I was at iProspect, we would occasionally be brought in to rescue a campaign that had launched poorly. The brief was usually the same: the product is good, the awareness is low, the sales are behind forecast. The root cause was almost always the same too. The commercial strategy had been built on assumptions that were never tested against the actual market.

In pharma, those assumptions tend to cluster around three things. First, that clinical efficacy translates automatically into prescriber preference. It does not. Second, that payers will follow the clinical evidence without commercial persuasion. They will not. Third, that patients will find the product once it is approved and available. They will not find it unless you build the infrastructure to reach them.

These are not new problems. They are well-documented. But they persist because the incentive structures inside pharmaceutical companies reward clinical milestones more visibly than commercial ones. Marketing is still treated as something that happens after the science is finished. That sequencing is the problem.

If you are building a go-to-market strategy across any complex B2B or regulated sector, the broader principles of go-to-market and growth strategy apply just as much in pharma as they do in SaaS or financial services. The variables are different. The logic is the same.

The Three Audiences That Must Be Addressed Separately

One of the clearest strategic errors in pharmaceutical go-to-market is collapsing three distinct audiences into a single campaign or messaging framework. Payers, prescribers, and patients have different information needs, different decision criteria, and different channels. Messaging that works for a medical affairs team presenting to a payer committee will not work for a GP reading a journal ad at 7pm. And neither of those will work for a patient trying to understand whether a treatment is right for them.

Payers need health economic evidence, budget impact models, and comparative effectiveness data. They are making population-level decisions under budget pressure. Prescribers need clinical differentiation, safety profiles, and practical guidance on patient selection. Patients, where direct-to-consumer communication is permitted, need clear, accessible language about what the treatment does, what to expect, and how to access it.

I have seen this same multi-audience challenge in other regulated sectors. In B2B financial services, for example, the compliance officer, the CFO, and the end user of a product all need completely different conversations. The principles I wrote about in B2B financial services marketing apply directly here: you cannot run a single message across stakeholders who have structurally different interests and expect it to land with any of them.

The fix is straightforward in principle. Build three distinct messaging architectures, each with its own value proposition, evidence base, and channel strategy. Then build a launch plan that sequences and coordinates those three tracks without letting them contradict each other. That coordination is harder than it sounds, particularly in large pharmaceutical organisations where medical affairs, market access, and commercial marketing often operate in separate silos.

When Go-To-Market Planning Should Actually Start

The answer most pharma marketers give when asked when GTM planning should begin is “at Phase III.” The honest answer is Phase II, and in some therapeutic areas, earlier. By the time you reach Phase III, the payer landscape is already forming opinions. Competitor products are already positioning. KOLs are already developing views. If your commercial team is not in those conversations, you are behind.

This is not a hypothetical. The gap between clinical readiness and commercial readiness is one of the most consistent patterns in pharmaceutical launch performance. Vidyard’s research on why go-to-market feels harder than it used to points to the same structural issue across sectors: the speed of market formation has accelerated, but internal planning cycles have not kept pace.

Early commercial planning in pharma means several things in practice. It means conducting payer advisory boards during Phase II to understand reimbursement barriers before you have a fixed label. It means building relationships with specialist KOLs before you need them to speak at launch symposia. It means developing your disease awareness strategy in the years before approval, so that the patient population and prescriber community are primed when the product becomes available. None of this requires a product to be approved. All of it requires a commercial team that is resourced and mandated to act early.

It also means your digital infrastructure needs to be built and tested well in advance. A product website that goes live two weeks before launch is not a commercial asset. It is a liability. Regulatory review of digital assets takes time. SEO takes time. Running a proper analysis of your web presence for sales and marketing readiness twelve months before launch, not twelve days, is the kind of operational discipline that separates well-prepared launches from reactive ones.

Channel Strategy in Pharma: What Has Changed and What Has Not

The pharmaceutical industry was slower than most to shift its channel mix away from rep-led, in-person detailing. That shift was already happening before 2020, and the years since have accelerated it considerably. But the industry’s response has often been to add digital channels on top of existing structures rather than rethink the channel mix from first principles.

The channels that matter most in pharma go-to-market today are not the same for every product type. For primary care products with large prescriber populations, digital channels including programmatic, search, and email can carry significant weight. For specialty and rare disease products, the prescriber population might be 200 or 2,000 specialists globally. In those cases, the channel strategy looks entirely different.

For specialty products, endemic advertising is one of the most underused tools in the pharma channel mix. Placing messages in the specialist environments where target prescribers already spend their professional attention, whether that is specialist journals, clinical education platforms, or specialty society channels, delivers contextual relevance that broad programmatic cannot match. I have seen this work in adjacent sectors where niche professional audiences require precision over volume. The logic is identical in pharma.

The other channel shift worth noting is in how pharma companies are approaching HCP outreach at the point of commercial launch. Rep access to physicians has declined structurally over the past decade. Many specialist practices have reduced or eliminated sales rep access entirely. That has pushed pharmaceutical companies toward a more sophisticated mix of digital outreach, medical education events, and peer-to-peer engagement. Some companies have also experimented with appointment-based outreach models to ensure that limited field force capacity is deployed against the highest-value targets rather than spread thinly across a broad call list.

BCG’s work on scaling agile approaches in complex organisations is relevant here. The pharmaceutical commercial model is not inherently agile. It is built around long planning cycles, regulatory constraints, and hierarchical approval processes. But within those constraints, there is more room for test-and-learn channel experimentation than most pharma marketing teams use.

The Organisational Structure Problem

One of the most consistent barriers to effective pharmaceutical go-to-market is not strategic. It is structural. Large pharmaceutical companies tend to organise commercial functions in ways that create friction at exactly the moments when coordination is most needed.

Medical affairs, market access, brand marketing, and the field force often report through different structures, with different incentives and different timelines. Medical affairs is focused on evidence generation and scientific exchange. Market access is focused on reimbursement dossiers and payer negotiations. Brand marketing is focused on the launch campaign. The field force is focused on call targets. None of these functions is wrong to focus on its own priorities. The problem is when there is no integrating layer that holds the commercial strategy together across all four.

This is a version of the same challenge I wrote about in the context of corporate and business unit marketing frameworks in B2B organisations. When the centre and the business units are not aligned on strategy, messaging, and measurement, the result is duplication, contradiction, and wasted spend. In pharma, add regulatory complexity and the stakes are even higher.

The solution is not a new org chart. It is a clear commercial leadership mandate that cuts across functions, with a shared launch plan that all functions are accountable to. In my experience running agencies that served large corporate clients, the companies that launched well were not necessarily the ones with the best creative or the biggest budgets. They were the ones where someone senior had the authority and the appetite to make the commercial functions work together.

Measurement and the Honest Approximation Problem

Pharmaceutical marketing has a measurement problem that is partly regulatory and partly cultural. On the regulatory side, the constraints on what can be tracked, particularly in patient-facing digital activity, are real and legitimate. On the cultural side, the industry has sometimes used regulatory complexity as a reason to avoid measurement discipline altogether.

The result is that many pharma marketing teams cannot tell you with any confidence what is driving prescriber behaviour. They have sales data. They have call activity data. They have some digital metrics. But the connection between marketing activity and commercial outcome is often asserted rather than demonstrated.

I judged the Effie Awards for several years. The Effies are specifically about marketing effectiveness, about demonstrating that a campaign produced a measurable commercial outcome. The entries from pharmaceutical companies were, on the whole, weaker on this dimension than entries from FMCG, retail, or financial services. Not because the campaigns were worse, but because the measurement infrastructure was less developed. That is a solvable problem.

Running proper digital marketing due diligence before and during a launch cycle is one of the most practical things a pharmaceutical marketing team can do to build measurement discipline. It means auditing what you can measure, what you cannot, and what proxies you will use for outcomes you cannot measure directly. Honest approximation, knowing what your data is actually telling you and what it is not, is more valuable than false precision.

Semrush’s overview of growth approaches across different sectors illustrates how measurement-led thinking drives better commercial decisions, regardless of industry. The pharma context adds constraints, but it does not remove the obligation to measure what you can and be honest about what you cannot.

Rare Disease and Specialty Products: A Different Commercial Logic

The commercial logic for a rare disease product is fundamentally different from the logic for a primary care blockbuster. The prescriber population might be 300 specialists globally. The patient population might be 5,000 people in a given market. Every element of the go-to-market model needs to reflect that reality.

In rare disease, the most important commercial relationships are often with patient advocacy organisations, specialist centres of excellence, and a small number of globally influential clinical researchers. Those relationships cannot be built through mass media. They require sustained, credible, scientific engagement over years, not months.

The patient identification challenge in rare disease is also distinct. Many patients with rare conditions are undiagnosed or misdiagnosed for years. A go-to-market strategy that only activates at the point of prescriber outreach is missing the earlier part of the patient experience where diagnosis is the bottleneck. Disease awareness campaigns, diagnostic support tools, and patient community engagement all need to be part of the commercial strategy, not additions to it.

Forrester’s thinking on intelligent growth models is relevant here: growth in niche markets requires a different kind of intelligence than growth in mass markets. The data signals are smaller, the relationships are more personal, and the margin for error is lower. That demands more precision in targeting, more care in relationship management, and more patience in timeline expectations.

For a deeper look at the broader strategic frameworks that underpin effective market entry across complex sectors, the go-to-market and growth strategy hub covers the principles that apply whether you are launching a specialty drug, a SaaS platform, or a financial services product.

What Good Pharmaceutical Go-To-Market Actually Looks Like

I want to be specific about this because the generic answer is not useful. Good pharmaceutical go-to-market does not look like a perfect launch plan assembled by a committee. It looks like a small number of clear commercial decisions made early, held consistently, and executed with discipline.

The first decision is the target patient population. Not the broad label population, but the specific patients where the product has the clearest clinical advantage and the most defensible reimbursement case. That population drives everything else: which prescribers matter most, which payers are the critical battles, which patient communities need to be reached.

The second decision is the core value proposition for each audience. Not a tagline. A clear, evidence-based statement of what the product does better than alternatives for a specific patient population, expressed differently for payers, prescribers, and patients.

The third decision is the channel mix, and specifically the trade-offs within it. You cannot be everywhere. A specialty product with a small prescriber population should not be spending the majority of its budget on broad programmatic. A primary care product with a prescriber population of 50,000 GPs cannot be reached through rep detailing alone. The channel mix should follow the audience, not the other way around.

The fourth decision is the measurement framework. What are the leading indicators that will tell you whether the launch is tracking ahead of or behind plan, before the sales data confirms it six months later? Prescriber activation rates, formulary listing progress, patient support programme enrolment, and digital engagement metrics can all serve as early signals if you define them in advance and track them consistently.

When I first took on a major client brief at Cybercom, I was handed the whiteboard pen mid-brainstorm when the founder had to leave for a meeting. My internal reaction was something close to panic. But the discipline that got me through it was not confidence. It was structure. Knowing what question you are actually trying to answer, and refusing to let the conversation drift into activity for its own sake, is as relevant in a pharmaceutical launch room as it is in any other commercial context. Marketing that cannot be connected to a commercial outcome is not really marketing. It is spending.

About the Author

Keith Lacy is a marketing strategist and former agency CEO with 20+ years of experience across agency leadership, performance marketing, and commercial strategy. He writes The Marketing Juice to cut through the noise and share what works.

Frequently Asked Questions